Neuromodulation Business Overview
FY2011 Revenue
Neuromodulation accounted for $1.59 billion, or 10%, of Medtronic's $15.9 billion in revenue in FY2011
Neuromodulation is the second-oldest and fourth-largest of Medtronic's business units. It was formed as we transferred our expertise in heart electrical stimulation to treat diseases and conditions involving the nervous system. Today, our products include neurostimulation systems and implantable drug delivery systems for chronic pain, common movement disorders, and urologic and gastrointestinal disorders.
Our products include:
- Medtronic Deep Brain Stimulation Therapy uses an implanted neurostimulation system to stimulate specific targets in the brain to treat advanced Parkinson's disease, essential tremor, and under humanitarian device exemptions, chronic, intractable primary dystonia and chronic, severe, treatment resistant obsessive compulsive disorder (OCD). Stimulation can be noninvasively adjusted to meet each patient's needs. DBS Therapy was first approved to in the US to treat essential tremor in 1997.
- Medtronic Pain Therapies™ encompass pain management therapies from our neurostimulation2 and drug delivery areas3. Both neurostimulation and intrathecal drug delivery can be effective options for patients with pain who are experiencing inadequate pain relief or uncomfortable side effects from their current pain treatments.
- Enterra® Therapy4 treats chronic nausea and vomiting associated with gastroparesis when conventional drug therapies are not effective. Gastroparesis is a stomach disorder in which food moves through the stomach more slowly than normal. In some patients, this condition results in severe, chronic nausea and vomiting, which cannot be adequately controlled by available drugs. These patients have difficulty eating and may require some form of tube feeding to ensure adequate nutrition.
- InterStim® Therapy for Urinary Control5 is the only implantable treatment to use electrical stimulation of the sacral nerves to manage the disabling symptoms of overactive bladder, including urinary urge incontinence and urinary retention.
- Intrathecal Baclofen Therapy (ITB TherapySM)6 eases intractable spasticity in patients with cerebral palsy, traumatic brain injury, and stroke by delivering Lioresal® Intrathecal (baclofen injection) directly to the intrathecal space in small, precisely controlled doses using a pump that is surgically placed in the abdomen.
References
- Important Safety Information for DBS Therapy
- Important Safety Information for Neurostimulators – Pain Conditions
- Important Safety Information for Drug Pumps – Pain Conditions
- Important Safety Information for Enterra® Therapy
- Important Safety Information for InterStim® Therapy
- Important Safety Information for ITB TherapySM
Last updated: 21 Nov 2011
- Print Page
- E-mail Page
- A
- A
- A Text Size